Plain-English translation of NCT07080216 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a combination of two drugs — and — to see if they can safely and effectively treat advanced cervical cancer. Some participants may also receive , an additional medication. The trial will first test different doses to find the safest combination, then expand to see how well the treatment works.
Advanced cervical cancer is a serious condition that needs better treatment options. This trial exists to see whether combining these newer medications might offer a more effective way to fight the disease while being tolerable for patients.
You likely qualify if…
You likely don't qualify if…
You would receive the combination medication as part of a carefully monitored treatment plan. The trial has two phases: first, researchers test different dose levels to find the safest combination; then, more participants receive the dose that worked best to see how effective the treatment is. You would have regular visits with the study team to check your health, manage any side effects, and monitor how well the treatment is working.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China
Safety & dosing / Early efficacy
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Enrollment target
~120 participants
Started
September 2025
Primary completion
August 2027
Age range
18 Years – 75 Years
Sex
Female only
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yongsheng Chu
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.